Early Breast Cancer News

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

Conference Coverage

Using TIL Score to Predict Overall Survival, Guide Trastuzumab De-Escalation Among Patients With HER2-Negative Early Breast Cancer

10/23/2024

Stephanie Holland ;

According to results from the updated analysis of the ShortHER trial, tumor-infiltrating lymphocyte score is predictive of overall survival and may potentially be used to guide trastuzumab de-escalation among patients with HER2-negative early...

According to results from the...

10/23/2024

Oncology

News

The TNBC-DX Test for Predicting pCR and Survival Outcomes Among Patients with Early-Stage Triple-Negative Breast Cancer

10/23/2024

Allison Casey ;

The TNBC-DX, a novel genomic test for patients with early-stage triple-negative breast cancer, was found to be effective at predicting a patient’s pCR and survival outcomes.

The TNBC-DX, a novel genomic...

10/23/2024

Oncology

Conference Coverage

Addition of Durvalumab and Oleclumab to Standard SBRT and Neoadjuvant Chemotherapy Shows Clinical Promise Among Patients With ER-Positive, HER2-Negative Early Breast Cancer

10/23/2024

Stephanie Holland ;

According to results from the phase 2 Neo-CheckRay trial, the addition of durvalumab and oleclumab to standard SBRT and neoadjuvant chemotherapy demonstrates promise among patients with ER-positive, HER2-negative, high-risk early breast...

According to results from the...

10/23/2024

Oncology

News

Neo/Adjuvant Pembrolizumab Significantly Improves Overall Survival for Patients With Early-Stage Triple-Negative Breast Cancer

10/09/2024

Stephanie Holland ;

According to results from the phase 3 KEYNOTE-522 trial, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab significantly improved overall survival among patients with early-stage triple-negative breast cancer.

According to results from the...

10/09/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Addition of Everolimus to Endocrine Therapy Did Not Improve Survival, Increased Toxicity Among Patients With High-Risk HR-Positive Early-Stage Breast Cancer

07/17/2024

Stephanie Holland ;

Results from the SWOG S127 study demonstrated that the addition of everolimus to endocrine therapy did not improve survival outcomes among patients with high-risk, HR-positive, early-stage breast cancer.

Results from the SWOG S127 study...

07/17/2024

Oncology

News

Trastuzumab Emtansine Improved Long-Term Outcomes Among Patients With HER2-Positive Early Breast Cancer

07/08/2024

Stephanie Holland ;

Long-term results from the phase 2 ATEMPT trial demonstrated that adjuvant trastuzumab emtansine improved long-term outcomes among patients with HER2-positive early-stage breast cancer.

Long-term results from the phase...

07/08/2024

Oncology

Conference Coverage

Addition of Carboplatin to Anthracycline and Taxane Therapy Improved Event-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer

06/17/2024

Stephanie Holland

According to results from the phase 3 PEARLY trial, the addition of carboplatin to standard anthracycline and taxane therapy significantly improved event-free survival among patients with early-stage triple-negative breast cancer.

According to results from the...

06/17/2024

Oncology

News

Ribociclib Added to Endocrine Therapy Improved Disease-Free Survival Among Patients With HR-Positive, HER2-Negative Early Breast Cancer

04/04/2024

Stephanie Holland

According to interim results from an international phase 3 trial, ribociclib plus either letrozole or anastrozole significantly improved disease-free survival among patients with HR-positive, HER2-negative early breast cancer.

According to interim results...

04/04/2024

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology